Simple Summary A new class of drugs, termed Immune Checkpoint Inhibitors, has revolutionized
cancer therapy during the last few years. Unfortunately, these drugs are only effective …

Endoplasmic reticulum (ER) aminopeptidases process antigenic peptide precursors to
generate epitopes for presentation by MHC class I molecules and help shape the antigenic …

The oxytocinase subfamily of M1 aminopeptidases, consisting of ER aminopeptidase 1 (ERAP1),
ER aminopeptidase 2 (ERAP2), and insulin-regulated aminopeptidase (IRAP), plays …

Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an intracellular enzyme that optimizes
the peptide cargo of major histocompatibility class I (MHC-I) molecules and regulates …

Aminopeptidases that generate antigenic peptides influence immunodominance and adaptive
cytotoxic immune responses. The mechanisms that allow these enzymes to efficiently …

The efficacy of cancer immunotherapy, including treatment with immune-checkpoint
inhibitors, often is limited by ineffective presentation of antigenic peptides that elicit T-cell-mediated …

Endoplasmic Reticulum aminopeptidase 1 and 2 are two homologous enzymes that help
generate peptide ligands for presentation by Major Histocompatibility Class I molecules. Their …

Insulin-regulated aminopeptidase (IRAP) is an enzyme with several important biological
functions that is known to process a large variety of different peptidic substrates, although the …

Presentation of antigenic peptides by MHCI is central to cellular immune responses against
viral pathogens. While adaptive immune responses versus SARS-CoV-2 can be of critical …

Inhibition of Insulin-Regulated Aminopeptidase is being actively explored for the treatment
of several human diseases and several classes of inhibitors have been developed although …